Tin tức & Cập nhật
Xem bài viết Đa khoa
Xem
Toripalimab consolidation after cCRT signals PFS and OS benefits in Chinese patients with LS-SCLC
A randomized, multicentre, phase II trial reports signals of improved progression-free survival (PFS) and overall survival (OS) with toripalimab consolidation after concurrent chemoradiotherapy (cCRT) in Chinese patients with limited-stage (LS) small-cell lung cancer (SCLC).
Sacituzumab tirumotecan still effective in pretreated metastastic TNBC despite dose modification
A detailed safety analysis of the phase III, multicenter, open-label, randomized, controlled OptiTROP-Breast01 trial suggests that sacituzumab tirumotecan (sac-TMT) has a manageable safety profile and that adverse events (AEs) can be effectively managed through dose modification and appropriate supportive care without compromising its efficacy in previously treated metastatic triple-negative breast cancer (mTNBC).
Sacituzumab govitecan plus pembrolizumab no better than monotherapy in metastatic NSCLC
Combination treatment with sacituzumab govitecan (SG) and pembrolizumab has resulted in a numerically longer progression-free survival (PFS) compared with pembrolizumab alone in patients with previously untreated metastatic nonsmall-cell lung cancer (NSCLC), but the difference did not reach statistical significance, according to the phase III EVOKE-03/KEYNOTE D46 study.
Switch to oral semaglutide benefits patients with overweight, obesity
Individuals with overweight or obesity lost a significant amount of weight 3 months after switching from an injectable formulation of semaglutide or tirzepatide to oral semaglutide, findings from the real-world OCTANE trial have shown. The switch was also associated with high treatment adherence and satisfaction.
ARTEMIS-008: Risvutatug rezetecan shows promise as new standard of care for relapsed SCLC
Treatment with the B7-H3-directed antibody-drug conjugate risvutatug rezetecan (Ris-Rez) results in significant improvements in overall survival (OS) compared with topotecan in patients with relapsed small-cell lung cancer (SCLC) who had progressed after receiving platinum-based chemotherapy, as shown by the results of the phase III ARTEMIS-008 trial.